Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome"
  2. Das, Subhendu K.; Kuzin, Vladislav; Cameron, Donald P.; Sanford, Suzanne; Jha, Rajiv Kumar; Nie, Zuqin; Rosello, Marta Trullols; Holewinski,Ronald; Andresson,Thorkell; Wisniewski, Jan; Natsume, Toyoaki; Price, David H.; Lewis, Brian A.; Kouzine, Fedor; Levens, David; Baranello, Laura
  3. Molecular Cell. 2022, Jan 6; 82(1): 140-158. e12.
  1. 2.   The indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2
  2. Marzi, Laetitia; Sun, Yilun; Huang, Shar-Yin N; James,Amy; Difilippantonio,Simone; Pommier, Yves
  3. Molecular cancer therapeutics. 2020, AUG; 19(8): 1589-1597.
  1. 3.   Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription
  2. Dalla Rosa, Ilaria; Zhang, Hongliang; Khiati, Salim; Wu, Xiaolin; Pommier, Yves
  3. Journal of Biological Chemistry. 2017, Dec 8; 292(49): 20162-20172.
  1. 4.   Structural genomic changes during mammalian ontogeny: a new dimension
  2. Shiao, Y. H.; Anderson, L. M.
  3. Epigenomics. 2012, Feb; 4(1): 1-4.
  1. 5.   N-Hydroxyethyl-4-aza-didehydropodophyllotoxin derivatives as potential antitumor agents
  2. Kumar, A.; Kumar, V.; Alegria, A. E.; Malhotra, S. V.
  3. European Journal of Pharmaceutical Sciences. 2011, Sep; 44(1-2): 21-26.
  1. 6.   Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
  2. Rapisarda, A.; Hollingshead, M.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Gehrs, B.; Raffeld, M.; Kinders, R. J.; Parchment, R.; Anver, M. R.; Shoemaker, R. H.; Melillo, G.
  3. Molecular Cancer Therapeutics. 2009 8(7): 1867-1877.
  1. 7.   Arylstibonic acids: Novel inhibitors and activators of human topoisomerase IB
  2. Kim, H.; Cardellina, J. H.; Akee, R.; Champoux, J. J.; Stivers, J. T.
  3. Bioorganic Chemistry. 2008 36(4-6): 190-197.
  1. 8.   Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice
  2. Hu, P. Q.; Hurwitz, A. A.; Oppenheim, M. J.
  3. Journal of Rheumatology. 2007, Nov; 34(11): 2243-2252.
  1. 9.   Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation by NSC 644221
  2. Creighton-Gutteridge, M.; Cardellina, J. H.; Stephen, A. G.; Rapisarda, A.; Uranchimeg, B.; Hite, K.; Denny, W. A.; Shoemaker, R. H.; Melillo, G.
  3. Clinical Cancer Research. 2007, Feb; 13(3): 1010-1018.
  1. 10.   NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity
  2. Bowen, C.; Stuart, A.; Ju, J. H.; Tuan, J.; Blonder, J.; Conrads, T. P.; Veenstra, T. D.; Gelmann, E. P.
  3. Cancer Research. 2007, Jan; 67(2): 455-464.
  1. 11.   Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4
  2. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettitt, R. K.
  3. Journal of Medicinal Chemistry. 2005, JUN 16; 48(12): 4087-4099.
  1. 12.   Introduction and overview. Perinatal carcinogenesis: growing a node for epidemiology, risk management, and animal studies
  2. Anderson, L. M.
  3. Toxicology and Applied Pharmacology. 2004, SEP 1; 199(2): 85-90.
  1. 13.   Autoreactive T cells recognize multiple epitopes on DNA topoisomerase I in sytemic sclerosis patients and in healthy controls
  2. Hu, P. Q.; Oriss, T.; Medsger, T.; Wright, T.
  3. Faseb Journal. 2004 18(5, Suppl. S): A836-A836.
  1. 14.   Identification of small molecule inhibitors of hypoxia- inducible factor 1 transcriptional activation pathway
  2. Rapisarda, A.; Uranchimeg, B.; Scudiero, D. A.; Selby, M.; Sausville, E. A.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2002 62(15): 4316-4324.
  1. 15.   Cellular pharmacology studies of shikonin derivatives
  2. Chen, X.; Yang, L.; Oppenheim, J. J.; Howard, O. M. Z.
  3. Phytotherapy Research. 2002 16(3): 199-209.
  1. 16.   Use of COMPARE analysis to discover new natural product drugs: Isolation of camptothecin and 9-methoxycamptothecin from a new source
  2. Zhou, B. N.; Hoch, J. M.; Johnson, R. K.; Mattern, M. R.; Eng, W. K.; Ma, J.; Hecht, S. M.; Newman, D. J.; Kingston, D. G. I.
  3. Journal of Natural Products. 2000 63(9): 1273-1276.
  1. 17.   Synergistic interactions between UCN-01 and various anticancer agents in vitro: Relationship to p53 function
  2. Monks, A.; Vaigro-Wolff, A.; Hose, C.; Sausville, E. A.; O'Connor, P. M.
  3. Annual Meeting of the American Association for Cancer Research. 1997, 38 A2157.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel